-
Tytuł:
-
A Novel, Highly Sensitive Quantitative Polymerase Chain Reaction Assay for the Diagnosis of Subarachnoid and Ventricular Neurocysticercosis and for Assessing Responses to Treatment.
-
Autorzy:
-
O'Connell EM; National Institute of Allergy and Infectious Diseases (NIAID), Laboratory of Parasitic Diseases (LPD), Helminth Immunology Section, Bethesda, Maryland.
Harrison S; National Institute of Allergy and Infectious Diseases (NIAID), Laboratory of Parasitic Diseases (LPD), Helminth Immunology Section, Bethesda, Maryland.
Dahlstrom E; NIAID, Research Technologies Branch, Bethesda, Maryland.
Nash T; NIAID, LPD, Clinical Parasitology Section.
Nutman TB; National Institute of Allergy and Infectious Diseases (NIAID), Laboratory of Parasitic Diseases (LPD), Helminth Immunology Section, Bethesda, Maryland.
-
Źródło:
-
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2020 Apr 15; Vol. 70 (9), pp. 1875-1881.
-
Typ publikacji:
-
Journal Article; Research Support, N.I.H., Intramural
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Jan. 2011- : Oxford : Oxford University Press
Original Publication: Chicago, IL : The University of Chicago Press, c1992-
-
MeSH Terms:
-
Neurocysticercosis*/diagnosis
Neurocysticercosis*/drug therapy
Taenia solium*/genetics
Animals ; Antigens, Helminth ; Enzyme-Linked Immunosorbent Assay ; Humans ; Polymerase Chain Reaction ; Reproducibility of Results ; Sensitivity and Specificity
-
References:
-
Int J Parasitol. 1992 Jul;22(4):471-7. (PMID: 1644522)
Am J Trop Med Hyg. 2018 Jun;98(6):1755-1762. (PMID: 29692305)
J Clin Pharmacol. 2019 Apr;59(4):548-556. (PMID: 30476351)
PLoS Negl Trop Dis. 2016 Mar 30;10(3):e0004578. (PMID: 27027771)
QJM. 2009 Oct;102(10):673-84. (PMID: 19556396)
BMC Vet Res. 2017 Mar 9;13(1):69. (PMID: 28274243)
PLoS Negl Trop Dis. 2016 Nov 9;10(11):e0005115. (PMID: 27828966)
Infect Genet Evol. 2016 Jun;40:357-367. (PMID: 26112071)
Expert Rev Anti Infect Ther. 2011 Jan;9(1):123-33. (PMID: 21171883)
J Clin Microbiol. 2011 Dec;49(12):4338-40. (PMID: 21976768)
Clin Chem. 2009 Apr;55(4):611-22. (PMID: 19246619)
N Engl J Med. 2014 Nov 13;371(20):1859-62. (PMID: 25390739)
Trop Med Int Health. 2013 May;18(5):608-14. (PMID: 23464616)
Acta Trop. 2015 Dec;152:60-65. (PMID: 26327445)
Microbes Infect. 2004 Nov;6(13):1199-204. (PMID: 15488739)
Lett Appl Microbiol. 2010 Apr;50(4):366-72. (PMID: 20149084)
J Clin Microbiol. 2003 Sep;41(9):4435-7. (PMID: 12958286)
Parasite Immunol. 1989 Jul;11(4):351-70. (PMID: 2674862)
Am J Trop Med Hyg. 2018 Apr;98(4):945-966. (PMID: 29644966)
PLoS Negl Trop Dis. 2013;7(3):e2096. (PMID: 23505587)
J Infect Dis. 2009 May 1;199(9):1345-52. (PMID: 19358669)
PLoS Negl Trop Dis. 2013 Nov 14;7(11):e2558. (PMID: 24244783)
-
Contributed Indexing:
-
Keywords: Taenia solium; PCR; biomarker; neurocysticercosis; subarachnoid disease
-
Substance Nomenclature:
-
0 (Antigens, Helminth)
-
Entry Date(s):
-
Date Created: 20190625 Date Completed: 20210106 Latest Revision: 20210106
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC7156770
-
DOI:
-
10.1093/cid/ciz541
-
PMID:
-
31232448
-
Background: Treatment of subarachnoid neurocysticercosis (NCC) is complicated, and assays that can guide treatment are not widely available. The reproducibility and scalability of molecular-based biomarkers would be of great use.
Methods: The Taenia solium genome was mined and primers and probes were designed to target repeats with the highest coverage; the most sensitive, specific, and efficient repeat (TsolR13) was selected for clinical testing. We tested 46 plasma samples and 36 cerebral spinal fluid (CSF) samples taken from patients with subarachnoid or ventricular disease using quantitative polymerase chain reaction (qPCR).
Results: The analytic sensitivity of TsolR13 was 97.3% at 240 attograms (ag) of T. solium genomic DNA and 100% analytic specificity. The clinical sensitivity in detecting active subarachnoid or ventricular disease in symptomatic patients was 100% in CSF and 81.3% in plasma. The predictive ability to distinguish active from cured disease was better for CSF (94.4% of those cured had negative qPCR results) than for plasma (86.7% of those cured tested negative). Some subjects also had plasma DNA detectable intermittently for years after being cured. Overall, the test performance was equivalent to T. solium antigen detection.
Conclusions: A qPCR test for the detection of the highly repetitive Tsol13 sequence has been developed and shown to be highly sensitive and specific for NCC, but also useful as a test of cure in CSF and for the definitive diagnosis of NCC in plasma.
(Published by Oxford University Press for the Infectious Diseases Society of America 2019.)
Comment in: Clin Infect Dis. 2020 Apr 15;70(9):1882-1883. (PMID: 31231751)